Batavia Insights
Living up to our mission to be a recognized Center of Excellence to the Life Sciences industry , we regularly share our knowledge through blogs and webinars.
Upcoming webinar:
Developing A Product Development Plan
Batavia Biosciences Announces Release of GMP Production Facility
This strategic move represents a significant leap in Batavia’s capabilities to deliver clinical manufacturing of viral vaccines and viral vectors.
Batavia Biosciences Announces Collaboration with Phoenix Nest Inc. to Accelerate Development of Therapeutics for Sanfilippo Syndrome
The collaboration aims to fast-track the development and production of recombinant human N-acetylglucosamine-6-sulfatase (rhGNS) for treatment of Sanfilippo syndrome, a rare genetic disorder.
Batavia partners in consortium to develop vaccine against Rift Valley fever
Batavia Biosciences is proud to be a key partner in an important initiative aimed at combating the deadly Rift Valley fever. We are thrilled to share that as part of the consortium working alongside esteemed partners such as Wageningen Bioveterinary Research, Bunyavax BV, CR2O BV, University of Veterinary Medicine Hannover, and Integrum Scientific, LLC, we are stepping up our efforts to bring a protective vaccine to East Africa, where Rift Valley fever is endemic.
Batavia Biosciences Joins the Alliance for Regenerative Medicine
Batavia Biosciences is excited to announce its new Alliance for Regenerative Medicine (ARM) membership, a premier international advocacy organization that brings regenerative medicines and advanced therapies to patients worldwide.
Batavia Accelerates Expansion of Biomanufacturing Facility
Batavia Biosciences announced significant progress in expanding its biomanufacturing facilities in Leiden, the Netherlands. Just two months after the first pile was drilled, Batavia continues to expedite this flagship project in conjunction with VILS and Provast.
The First Pile Event
Join us as we celebrate the groundbreaking of our new commercial GMP manufacturing facility.
Accelerating Viral Vector and Vaccine Development: Beware Of The Pitfalls of Scale-Up
Why is scale-up of viral vaccines and viral vector products for clinical phase testing so challenging? Here are 5 of the biggest pitfalls.
What Type of CDMO is the Right Fit For You?
When it comes to outsourcing, there is often confusion about the type of partner that is most appropriate for a project. In our previous article, we discussed the difference between a CRO, CMO and CDMO. In this article, we would like to zoom in on the different type...
How the Netherlands became a key player for vaccine development
The Netherlands has a long history in the life sciences industry. Especially in the field of vaccine development and manufacturing, this small country has always played a significant role. Lately, the rich history proved a fertile ground for developing and...
Solving challenges in manufacturing viral vector based ATMPs
Written by expert: Kai, Technical Lead The obstacles of viral vector production Over the last decade, the scientific community has witnessed several breakthroughs in the field of gene therapy and immuno-oncology. These breakthroughs have propelled the interest in the...
Batavia: Lentivirus for first patient NL
Batavia produces lentivirus for first patient in the Netherlands successfully treated with stem cell gene therapy
How to Work With a CDMO for Viral Vectors: 5 Steps to Success
5 Steps to successfully select a specialized CDMO for Viral Vectors and outsource your manufacturing project.
How to Turn An Innovative Drug Candidate into a Commercial Success – The Product Development Plan Explained
Behind every successful drug is a well-crafted product development plan. Read why and how to use this tool to formulate a winning strategy.
Guide To Viral Vector Production & Development
Explore this guide to viral vector process development and scale-up and accelerate your journey from bench to bedside.
Biotech Startups – Understanding The Ecosystem For Success
Today’s ecosystem for drug development has more symbiotic relationships between VC-backed pharma and biotech startups working to diffuse risk
How Important Is The Matrix Effect in Analyzing Bioprocess Samples?
How important is evaluation of the matrix effects when analyzing bioprocess samples? What are the best approaches to evaluate the effect? And in what situations is the matrix effect acceptable?
Adenovirus Vectors in Gene Therapy – Vaccine Development & Delivery Tools
Adenovirus vectors are vital to gene therapy, vaccine development, and cancer virotherapies. Learn more about these important delivery tools.
Taking your adenoviral vector product from R&D to the clinic
The road from R&D to final production of an adenoviral vector product is well trodden. Here is information to help you on your journey.
Driving Down COGs of Viral Vector-Based Biopharmaceuticals
How do you keep cost of goods (COGs) for viral vector-based medicines within reason to develop a product that is both affordable and financially viable?
Batavia Biosciences Optimizes Global Quality Assurance with Veeva Vault Quality Suite
Batavia, a globally trusted CDMO, optimizes QA by boosting GxP compliance and inspection readiness with Veeva quality applications
Gene therapy developers see an expanded viral toolbox
Being a gene therapy developer, Batavia Biosciences’ Global Technical Director, Alfred Luitjens was interviewed topic by GEN.
Gene therapies push AAV vector production
Our Technical Lead, Kai Touw, has been interviewed by BioPharm International to discuss the challenges of AAV vector production for gene therapy.
Adenoviral Vector Platform: Past & Current Challenges
Adenoviral vectors are an extremely important tool in developing therapies and vaccines. Read more about their impressive track record here.
New Head of BD: Ron van Eijsden
Batavia Biosciences appoints Ron van Eijsden, Ph.D., as Head of Business Development
Increased Capacity in The Netherlands
Batavia Biosciences increases capacity for viral vectors and vaccine R&D in Netherlands.
ViE Award
Batavia wins 2022 ViE Award for Best Process Development
Batavia manufactures LASV vaccine candidate for IAVI who today announced the first vaccinations of their Lassa fever vaccine candidate
Batavia Biosciences would like to congratulate IAVI on their press release, as today they’ve announced volunteers in Monrovia, Liberia have been vaccinated with IAVI’s novel vaccine candidate against Lassa fever virus (LASV) in a Phase I clinical trial, named IAVI...
How to devise a drug development plan that actually works
A well-crafted product development plan (PDP) can play a pivotal role in the development and commercialization of a new drug product, but creating one takes time, commitment, and a lot of hard work. After all that effort, will your PDP be the magic bullet...
GMP Viral Vector and Viral Vaccine Production: Is Outsourcing to a CDMO the Answer For Your project?
A CDMO optimizes and scales viral vaccine production for clinical and commercial manufacturing. Here’s how.
Collaboration with IAVI on VSV-Vector
IAVI and Batavia Biosciences today announced their partnership to accelerate the development of vaccines for emerging infectious diseases (EIDs).
Do Fixed-Bed Bioreactors Provide A Solution to Viral Vector Shortages?
A blog to guide you through some of our team’s experiences with fixed bed reactors for virus manufacturing.
Developing stable cell lines for difficult to express proteins: laronidase example
Product yield from mammalian cell lines is a critical economic driver. This is a challenge for difficult to express proteins.
Challenges In Virus-Based Manufacturing In GMP
Whether it is a vector vaccine, gene therapy or oncolytic virus, there are challenges in virus manufacturing that cannot be overlooked.
Latest Advancements In Bioprocess Intensification For Efficient Biopharmaceutical Production
High costs manufacturing prevents segments of the population from accessing medicines. This could be solved by bioprocess intensification.
Analytical Assay Development: Go ALL the way
The truth is; the accuracy and robustness of any process under development or manufacturing outcome is only as good as the reliability of the assays needed to understand the process.
$14.3M grant to deliver affordable measles & rubella vaccines
Grant from the Bill & Melinda Gates Foundation will support Univercells and partner Batavia Biosciences to develop a cost-effective manufacturing process and proceed towards the successful commercialization of measles and rubella vaccines.
Batavia Biosciences partners with the University of Tokyo to develop a vector-based vaccine against Nipah virus
Batavia Biosciences partners with the University of Tokyo to develop a vector-based vaccine against Nipah virus
Improved selection of protein-producing cell lines using a scale-down approach – a case study
The selection of a stable protein expressing cell line is a tedious process in which two substantially different approaches are used.
Genetic stability studies: could process parameters change your virus?
By adjusting your process conditions, you may increase productivity, but how does it influence the genetic stability?
Selecting A GMP Manufacturing Partner
When selecting a partner for clinical GMP manufacturing there are several guidelines to follow to prevent surprises during the project.
Tackling the capacity bottleneck in downstream processing of viral vectors
Written by expert: Evert, Associate Director DSP With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand. A steady increase of product titers and the corresponding change in...
The need to increase production yield of therapeutic proteins
To increase production yield, allows drastic reductions in market price. Manufacturing scale can be reduced, hence the cost of goods will be lower.
Assay For Poliovirus Quantification
Novel HPLC assays allow for better biopharmaceutical development and a case study of poliovirus quantification.
Univercells and consortium partners Batavia Biosciences and Natrix Separations Received $12 Million Grant by Bill & Melinda Gates Foundation to Radically Reduce Vaccine Costs for Developing Countries
Brussels, Belgium, December 15, 2016 – Univercells announced today that it has been awarded a $12 million grant by the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform with the objective of radically lowering...
Batavia Biosciences Announces Release of GMP Production Facility
This strategic move represents a significant leap in Batavia’s capabilities to deliver clinical manufacturing of viral vaccines and viral vectors.
Batavia enters commercial manufacturing
Read how Batavia Biosciences will extend its CDMO services portfolio to include commercial manufacturing services.
Batavia At LBSP ATMP TechTalks
Eize De Boer featured as prominent speaker at ATMP-themed TechTalks in the Leiden Bio Science Park.
LUMC & Batavia Biosciences Burst the Bubble
In this article, you can read about the journey UMC & Batavia undertook to cure a first patient with SCID in history.
Batavia Biosciences is expanding its viral vector process development capacity in Massachusetts
Today, Batavia Biosciences announces the expansion of its process development facilities in Woburn, MA, United States to accommodate the increasing market demand for viral vectors.
Univercells and consortium partners Batavia Biosciences and Natrix Separations Received $12 Million Grant by Bill & Melinda Gates Foundation to Radically Reduce Vaccine Costs for Developing Countries
Brussels, Belgium, December 15, 2016 – Univercells announced today that it has been awarded a $12 million grant by the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform with the objective of radically lowering...
